[go: up one dir, main page]

DE60129314D1 - Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen - Google Patents

Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen

Info

Publication number
DE60129314D1
DE60129314D1 DE60129314T DE60129314T DE60129314D1 DE 60129314 D1 DE60129314 D1 DE 60129314D1 DE 60129314 T DE60129314 T DE 60129314T DE 60129314 T DE60129314 T DE 60129314T DE 60129314 D1 DE60129314 D1 DE 60129314D1
Authority
DE
Germany
Prior art keywords
liver fibrosis
diagnosis
help
serum marker
timp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60129314T
Other languages
English (en)
Other versions
DE60129314T2 (de
Inventor
Michael Voelker
Michael Becka
Werner Kroll
Andreas Knorr
Sylvia Unger
Mathias Gehrmann
Guido Hennig
Elmar-Reinhold Burchardt
Michael J Arthur
Alastair D Burt
Massimo Pinzani
Detlef Schuppan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer Corp
Original Assignee
Bayer AG
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00109063A external-priority patent/EP1150123B1/de
Application filed by Bayer AG, Bayer Corp filed Critical Bayer AG
Application granted granted Critical
Publication of DE60129314D1 publication Critical patent/DE60129314D1/de
Publication of DE60129314T2 publication Critical patent/DE60129314T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
DE60129314T 2000-04-28 2001-04-26 Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen Expired - Lifetime DE60129314T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00109063 2000-04-28
EP00109063A EP1150123B1 (de) 2000-04-28 2000-04-28 Diagnose von Leberfibrose mit Hilfe von Serummarkeralgorithmen
IT2001MI000813A ITMI20010813A1 (it) 2000-04-28 2001-04-13 Valutazione di fibrosi del fegato con algoritmi basati su marcatori del siero
ITMI000813 2001-04-13
PCT/EP2001/004696 WO2001086304A2 (en) 2000-04-28 2001-04-26 Diagnostic of liver fibrosis with serum marker algorithms

Publications (2)

Publication Number Publication Date
DE60129314D1 true DE60129314D1 (de) 2007-08-23
DE60129314T2 DE60129314T2 (de) 2008-07-17

Family

ID=29713312

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60129314T Expired - Lifetime DE60129314T2 (de) 2000-04-28 2001-04-26 Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen

Country Status (7)

Country Link
US (1) US7141380B2 (de)
EP (1) EP1283989B1 (de)
AT (1) ATE366939T1 (de)
AU (1) AU6738001A (de)
DE (1) DE60129314T2 (de)
ES (1) ES2288962T3 (de)
WO (1) WO2001086304A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7668661B2 (en) 2000-04-28 2010-02-23 Siemens Healthcare Diagnostics Inc. Liver disease-related methods and systems
US6631330B1 (en) 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
EP1588159A4 (de) * 2002-12-24 2008-03-12 Biosite Inc Verfahren und system zur erkennung von erkrankungen mittels markerkombinationen
EP1577385B1 (de) * 2002-12-24 2010-03-24 Nitto Boseki Co., Ltd. Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit
US7670764B2 (en) * 2003-10-24 2010-03-02 Prometheus Laboratories Inc. Methods of diagnosing tissue fibrosis
FR2870348B1 (fr) * 2004-05-14 2010-08-27 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet
ATE354097T1 (de) * 2004-08-12 2007-03-15 Hoffmann La Roche Verfahren zur diagnose von leberfibrose.
US7809170B2 (en) 2006-08-10 2010-10-05 Louisiana Tech University Foundation, Inc. Method and apparatus for choosing and evaluating sample size for biometric training process
KR100999720B1 (ko) 2008-11-13 2010-12-08 아주대학교산학협력단 간 경변 진단을 위한 분석방법
RU2505821C2 (ru) 2008-12-02 2014-01-27 Индастриал Текнолоджи Ресерч Институт Биомаркеры, пригодные при диагностике фиброза печени
KR101018960B1 (ko) 2009-02-23 2011-03-02 아주대학교산학협력단 유의성있는 간섬유화 진단을 위한 분석 방법
CN102334122B (zh) 2009-02-26 2018-04-27 昂热大学 肝纤维化或肝硬化的改进诊断
JP5612067B2 (ja) 2009-03-19 2014-10-22 ユニバーシティ ダンガース 肝線維化進行を評価するための非侵襲的方法
CN102020715B (zh) * 2010-10-22 2012-09-05 上海贝西生物科技有限公司 一种抗ⅲ型前胶原氨基末端肽单克隆抗体及其用途
EP2684513A1 (de) * 2012-07-13 2014-01-15 Universite D'angers Verfahren zur Bereitstellung zuverlässiger, nichtinvasiver Diagnosetests
FR3023003B1 (fr) 2014-06-27 2016-07-15 Bio-Rad Innovations Combinaison synergique de biomarqueurs pour la detection et l'evaluation d'une fibrose hepatique
EP3491388B1 (de) 2016-08-01 2021-09-01 Centre Hospitalier Universitaire d'Angers Multi-zielgerichteten fibrosetests
PL425251A1 (pl) * 2018-04-17 2019-10-21 Uniwersytet Kazimierza Wielkiego Panel analityczny jako jeden z elementów wieloaspektowego procesu ustalającego stan zdrowia, dysfunkcji wątroby dla osób z zespołem zależności alkoholowej
AU2023258028A1 (en) * 2022-04-20 2024-09-19 Siemens Healthcare Diagnostics Inc. Biomarkers for idiopathic pulmonary fibrosis and methods of producing and using same
ES2957479A1 (es) * 2022-06-07 2024-01-19 Baigene S L Metodo de obtencion de datos utiles para la prediccion del riesgo de un sujeto de sufrir fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060255A (en) * 1997-10-03 2000-05-09 Tosoh Corporation Type IV collagen high molecular form and production and diagnostic use thereof

Also Published As

Publication number Publication date
WO2001086304A3 (en) 2002-04-04
AU6738001A (en) 2001-11-20
DE60129314T2 (de) 2008-07-17
ATE366939T1 (de) 2007-08-15
EP1283989A2 (de) 2003-02-19
ES2288962T3 (es) 2008-02-01
EP1283989B1 (de) 2007-07-11
WO2001086304A2 (en) 2001-11-15
US7141380B2 (en) 2006-11-28
US20040053242A1 (en) 2004-03-18

Similar Documents

Publication Publication Date Title
DE60129314D1 (de) Diagnose von leberfibrose mit hilfe von serummarkeralgorithmen
ATE437371T1 (de) Verfahren und kit zum nachweis des frühstadiums einer nierentubuluszellenverletzung
ATE331960T1 (de) Diagnose von myokardinfarkt und akutem koronarsyndrom durch kombination von markern
ATE230487T1 (de) Verfahren zur frühen diagnose von carcinomen
DE69842017D1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
ATE312349T1 (de) Differentielle diagnose von neurodegeneration
WO2006081473A3 (en) Methods for diagnosis and prognosis of epithelial cancers
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
DE60321552D1 (de) Neues verfahren für die diagnose und prognose von malignen erkrankungen
DE60117592D1 (de) Diagnose von pre-eclampsia
ATE395812T1 (de) Methoden zur vorhersage eines schwangerschaftsergebnisses bei einer testperson mit hilfe eines hcg-tests
ATE375517T1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
BR0102323A (pt) Ensaios para medição de fragmentos de colágenotipo ii na urina
DE10082504D2 (de) Indikatorpeptid zur Diagnose und/oder Vorhersage von cardiovasculären und /oder endothelialen Erkrankungen, Antikörperzusammensetzung und immunoassay
Siennicka et al. Spatial differences of matrix metalloproteinase-2 and matrix metalloproteinase-9 within abdominal aortic aneurysm wall and intraluminal thrombus
FR2795823B1 (fr) Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
ATE277352T1 (de) Einetenascin-c isoform als marker für neoplasmen
DE602004017317D1 (de) Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome
ATE440282T1 (de) Verfahren zum bestimmen der entzündungshemmenden wirkung eines peptids
Gaggar et al. Biologic markers of mortality in acute lung injury
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs
ATE353544T1 (de) Verwendung des proteins masp als marker für kolorektale karzinome
DE602004005859D1 (de) Verwendung des proteins crabp ii (cellular retinoic acid-binding protein ii) als marker für brustkrebs
ATE386935T1 (de) Verfahren zur auswahl bioaktiver wirkstoffe durch lumineszenzkopplung und lebendes zellensystem dafür

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1283989

Country of ref document: EP

Representative=s name: PETER BERG, 80339 MUENCHEN, DE